D'Amico Alex, Mir Nabiel, Wilkerson Hunter, Andrikopoulou Efstathia, Kanter Julie
School of Medicine, University of Alabama at Birmingham, 1670 University Blvd, Birmingham, AL 35233, USA.
Department of Medicine, University of Alabama at Birmingham, 1808 7th Ave South, Birmingham, AL 35233, USA.
Eur Heart J Case Rep. 2020 Dec 28;5(2):ytaa555. doi: 10.1093/ehjcr/ytaa555. eCollection 2021 Feb.
Individuals with sickle cell disease (SCD) are at risk for painful crises and long-term cardiopulmonary morbidity. Echocardiogram is recommended if signs or symptoms of cardiopulmonary disease develop in previously asymptomatic patients, or worsen in those with known disease. Second-generation echocardiogram contrast agents (ECAs) improve the diagnostic capacity of echocardiogram; however, these agents have risks in SCD populations that have yet to be investigated.
We report a case series of two patients who experienced vaso-occlusive crises following administration of the ECA, Definity. Both patients were referred for echocardiogram from our institution's sickle cell clinic because of concern for SCD-related cardiopulmonary complications. Both patients were in their usual state of health at the time of their exams. The first patient experienced acute back and hip pain minutes after receiving Definity and was diagnosed with acute vaso-occlusive crisis requiring admission for 6 days for pain management. The second patient developed dyspnoea and chest pain within 90 min of her echocardiogram. She was diagnosed with acute chest syndrome and admitted for further management. Her hospitalization was complicated by hyper-haemolysis and multiple organ failure syndrome. After 13 days, she was discharged home.
The safety profile of ECAs has not been fully evaluated and warrants further study in individuals with SCD. Proposed mechanisms for our observations include the release of pro-inflammatory metabolites from Definity contrast agent's shell and ultrasound-induced haemolysis secondary to ECA administration. Alternative imaging modalities and proper precautions should be considered when evaluating cardiopulmonary function in this patient population.
镰状细胞病(SCD)患者有发生疼痛性危象和长期心肺疾病的风险。如果先前无症状的患者出现心肺疾病的体征或症状,或已知患有该病的患者病情恶化,则建议进行超声心动图检查。第二代超声心动图造影剂(ECAs)可提高超声心动图的诊断能力;然而,这些药物在SCD人群中的风险尚未得到研究。
我们报告了一个包含两名患者的病例系列,这两名患者在使用ECAs Definity后发生了血管闭塞性危象。由于担心与SCD相关的心肺并发症,两名患者均从我们机构的镰状细胞诊所转诊进行超声心动图检查。两名患者在检查时均处于平常的健康状态。第一名患者在接受Definity后几分钟出现急性背部和髋部疼痛,被诊断为急性血管闭塞性危象,需要住院6天进行疼痛管理。第二名患者在超声心动图检查后90分钟内出现呼吸困难和胸痛。她被诊断为急性胸部综合征并入院进一步治疗。她的住院治疗因高溶血和多器官功能衰竭综合征而复杂化。13天后,她出院回家。
ECAs的安全性尚未得到充分评估,需要在SCD患者中进一步研究。我们观察结果的可能机制包括Definity造影剂外壳释放促炎代谢产物以及ECA给药后超声诱导的溶血。在评估该患者群体的心肺功能时,应考虑替代成像方式和适当的预防措施。